<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03279536</url>
  </required_header>
  <id_info>
    <org_study_id>WHH</org_study_id>
    <nct_id>NCT03279536</nct_id>
  </id_info>
  <brief_title>Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing</brief_title>
  <acronym>TDI</acronym>
  <official_title>Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Woman's Health University Hospital, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Woman's Health University Hospital, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consisted of 60 cases. All the cases of pregnant women are 4 months to 8 months of&#xD;
      pregnancy. The cases divided into 30 pregnant women's were given iron supplementation without&#xD;
      health education and another 30 were given iron supplementation and health education for&#xD;
      comparison between them. Comparative between hemoglobin levels before and after medication.&#xD;
      Treatment of iron deficiency anemia with iron supplementation received for one month.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator will divide the participants into two groups e.g. group (A) and group (B)&#xD;
      according to Hemoglobin level and receiving of oral supplementation for IDA accompanied with&#xD;
      health education in case of group (A) and without health education in case of group (B). Then&#xD;
      the investigator asked patient to sign the document of her investigations result to receive&#xD;
      iron supplementation.&#xD;
&#xD;
        -  After that, the investigator observes hemoglobin's Level, when it less than &gt;11g/dl, the&#xD;
           patient will be the group (A) who will receive oral iron supplementation and health&#xD;
           education.&#xD;
&#xD;
        -  Group (B) who will receive Total Dose Infusion (TDI) without health education.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A will receive oral lactoferrin &amp; group B will receive Total dose infusion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in Hb concentration</measure>
    <time_frame>4- 8 weeks</time_frame>
    <description>measure the change in Hb concentration from baseline to week 4 after oral Lactoferrin treatment and relieve of symptoms of anemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure the change in serum iron, serum ferritin</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>measure the change in serum iron, serum ferritin based on comparison between oral lactoferrin with health education &amp; TDI from hospital routine care.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Oral Lactoferrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A is 120 mg of Oral lactoferrin for 4 weeks Intervention: The participants 66 will receive oral Lactoferrin 120mg for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total dose infusion (TDI) iron dextran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B is a parenteral total dose infusion (TDI) of LMW iron dextran 20mg/kg body weight for 4 weeks Intervention: The participants 33 will receive parental iron 20mg/kg body weight for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Oral lactoferrin</intervention_name>
    <description>Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.</description>
    <arm_group_label>Oral Lactoferrin</arm_group_label>
    <other_name>Oral Fizzing Lactoferrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>TDI of LMW iron dextran</intervention_name>
    <description>Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously</description>
    <arm_group_label>Total dose infusion (TDI) iron dextran</arm_group_label>
    <other_name>Parental dextran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant Women aged &gt;18 years&#xD;
&#xD;
          2. Hemoglobin&lt;10g/dl&#xD;
&#xD;
          3. Gestational age between 14-28 weeks&#xD;
&#xD;
          4. Singleton pregnancy&#xD;
&#xD;
          5. Willingness to participate and signing the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Anemia predominantly caused by factors other than IDA (e.g. anemia with untreated B12&#xD;
             or foliate deficiency, hemolytic anemia),&#xD;
&#xD;
          2. Iron overload or disturbances in utilization of iron (e.g. hemochromatosis and&#xD;
             haemosidrosis).&#xD;
&#xD;
          3. Decompensated liver cirrhosis and active hepatitis (ALAT&gt;3 times upper limit of&#xD;
             normal).&#xD;
&#xD;
          4. Active acute or chronic infections (assessed by clinical judgment supplied with white&#xD;
             Blood Cells (WBC) and C - reactive protein (CRP).&#xD;
&#xD;
          5. Rheumatoid arthritis with symptoms or signs of active inflammation.&#xD;
&#xD;
          6. Multiple allergies.&#xD;
&#xD;
          7. Known hypersensitivity to parental iron or any recipients in the investigational drug&#xD;
             products.&#xD;
&#xD;
          8. Erythropoietin treatment within 8 weeks prior to the screening visit.&#xD;
&#xD;
          9. Other iron treatment within 8 weeks prior to the screening visit.&#xD;
&#xD;
         10. Planned elective surgery during the study.&#xD;
&#xD;
         11. Participation in any other clinical within 3 months prior to the screening.&#xD;
&#xD;
         12. Any other medical condition e.g. malignancy, uncontrolled hypertension, unstable&#xD;
             ischemic heart disease, or uncontrolled diabetes mellitus.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Warda Helmy, BSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>WHH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women Health Hospital</name>
      <address>
        <city>Asyut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Woman's Health University Hospital, Egypt</investigator_affiliation>
    <investigator_full_name>Howieda Fouly</investigator_full_name>
    <investigator_title>PhD of Obstetric &amp; Gynecologic Nursing</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
    <mesh_term>Dextrans</mesh_term>
    <mesh_term>Iron-Dextran Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publishing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>3-6 months</ipd_time_frame>
    <ipd_access_criteria>Introduction, Methodology, data analysis, Findings, Discussion &amp; Conclusion</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

